DUETNCT07946367
Dual-targeting of B & T Cell Pathways Evaluation Trial
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Timeframe: Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
Timeframe: Up to 1 year post-dosing
To monitor immune response to DFI205
Timeframe: Up to 1 year post-dosing
Secondary (4)
To evaluate the ability of DFI205 to induce an objective response in adults with RA
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Arms and interventions
Phase 1 Single Ascending Dose EscalationExperimental
Intravenous (IV) infusion of DFI205 at ascending dose levels.
Phase 2a Multi-DoseExperimental
DFI205 monthly IV infusions at the recommended Phase 2 dose
Drugs: DFI205 bispecific antibody
Sites
1 site in 1 country
- Universitaetsklinikum Erlangen AöRErlangen, Germany